Results 21 to 30 of about 21,132 (237)
Alimentary Pharmacology and Therapeutics, 2023 Drugs which can inhibit nausea/vomiting and/or increase gastric emptying are used to treat gastroparesis, mostly ‘off‐label’. Within each category, they act at different targets and modulate different physiological mechanisms.
G. Sanger, P. Andrews
semanticscholar +1 more source
Targeting the pylorus in gastroparesis: From physiology to endoscopic pyloromyotomy
Neurogastroenterology and Motility, 2023 The pylorus plays a key role in the control of gastric content outflow. Impairment of pyloric physiology has been observed in gastroparesis, particularly when associated with diabetes mellitus or opioid intake or after antireflux surgery.
Heithem Soliman, G. Gourcerol
semanticscholar +1 more source
Neurogastroenterology and Motility, 2023 Both gastric electrical stimulation (GES) and gastric‐peroral endoscopic myotomy (G‐POEM) can be offered to patients with gastroparesis and predominant nausea and vomiting.
G. Gourcerol +12 more
semanticscholar +1 more source
Alimentary Pharmacology and Therapeutics, 2023 Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5‐HT1 receptor agonist, may improve fundic accommodation.
H. Parkman +17 more
semanticscholar +1 more source
Clinical Gastroenterology and Hepatology, 2019 A reader raises questions about diabetic gastroparesis (April 2019).
Mostafa Elfeky +2 more
semanticscholar +4 more sources
Gastroenterology, 2021 BACKGROUND & AIMS While gastroparesis carries a considerable healthcare and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient ...
Y. Ye +5 more
semanticscholar +1 more source
Prevalence of delayed gastric emptying in patients with gastroparesis‐like symptoms
Alimentary Pharmacology and Therapeutics, 2023 The European consensus defined gastroparesis as a condition characterised by delayed gastric emptying (GE) in the absence of mechanical obstruction, with a symptom pattern of predominant nausea and/or vomiting and overlapping postprandial distress ...
I. Huang +8 more
semanticscholar +1 more source
Imaging in Gastroparesis: Exploring Innovative Diagnostic Approaches, Symptoms, and Treatment
Life, 2023 Gastroparesis (GP) is a chronic disease characterized by upper gastrointestinal symptoms, primarily nausea and vomiting, and delayed gastric emptying (GE), in the absence of mechanical GI obstruction. The underlying pathophysiology of GP remains unclear,
F. Mandarino +7 more
semanticscholar +1 more source
Neurogastroenterology and Motility, 2023 Gastrointestinal (GI)‐specific anxiety has been identified as a treatment target in irritable bowel syndrome. However, GI‐specific anxiety has been understudied in other GI functional/motility disorders.
Samuel E Tanner +4 more
semanticscholar +1 more source
Computational modeling of drug dissolution in the human stomach: Effects of posture and gastroparesis on drug bioavailability. [PDF]
The Physics of Fluids, 2022 The oral route is the most common choice for drug administration because of several advantages, such as convenience, low cost, and high patient compliance, and the demand and investment in research and development for oral drugs continue to grow.
Jae Ho Lee +4 more
semanticscholar +1 more source